利拉鲁肽联合二甲双胍用于2型糖尿病合并冠心病治疗的临床效果评估  

Clinical Evaluation of Liraglutide Combined with Metformin in the Treatment of Type 2 Diabetes Mellitus Complicated with Coronary Heart Disease

作　　者：李文正[1] LI Wenzheng(Department of Internal Medicine,Feixian People's Hospital,Linyi,Shandong Province,273400 China)

机构地区：[1]费县人民医院内科,山东临沂273400

出　　处：《糖尿病新世界》2023年第7期80-83,共4页Diabetes New World Magazine

摘　　要：目的探究利拉鲁肽联合二甲双胍用于2型糖尿病合并冠心病治疗的临床效果。方法选取2020年1月—2022年4月山东费县人民医院收治的2型糖尿病合并冠心病患者84例为研究对象,按照数字随机表法将其分为对照组和研究组,每组41例。对照组应用二甲双胍+通络胶囊治疗,研究组在对照组基础上应用利拉鲁肽治疗,对比两组临床治疗效果。结果治疗后,研究组FPG、2 hPG均明显低于对照组,差异有统计学意义(P<0.05);治疗后,研究组HDL-C、LDL-C、TG、TC均明显优于对照组,差异有统计学意义(P<0.05);研究组治疗有效率(95.12%)高于对照组(78.05%),差异有统计学意义(P<0.05);研究组不良反应发生率(17.07%)和对照组(19.51%)比较,差异无统计学意义(P>0.05)。结论在2型糖尿病合并冠心病治疗中,利拉鲁肽与二甲双胍联合治疗取得了良好效果,对于稳定患者血糖水平,降低患者血脂状况具有显著意义,治疗安全有效。Objective To explore the clinical effect of liraglutide combined with metformin in the treatment of type 2 diabetes mellitus complicated with coronary heart disease.Methods From January 2020 to April 2022,84 patients with type 2 diabetes combined with coronary heart disease admitted to Shandong Feixian People's Hospital were selected as the study subjects,and they were divided into a control group and a study group according to the method of digital random table,with 41 cases in each group.The control group was treated with metformin and tongluo capsule,while the study group was treated with liraglutide on the basis of the control group.The clinical effects of the two groups were compared.Results After treatment,the FPG and 2-hour PG in the study group were significantly lower than those in the control group,the difference was statistically significant(P<0.05).After treatment,the HDL-C,LDLC,TG,and TC in the study group were significantly better than those in the control group,the difference was statistically significant(P<0.05).The effective rate of treatment in the study group(95.12%)was higher than that in the control group(78.05%),the difference was statistically significant(P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the study group(17.07%)and the control group(19.51%)(P>0.05).Conclusion In the treatment of type 2 diabetes complicated with coronary heart disease,liraglutide combined with metformin has achieved good results.It has significant significance in stabilizing blood sugar levels,and reducing blood lipid status in patients.The treatment is safe and effective.

关 键 词：2型糖尿病合并冠心病 利拉鲁肽 二甲双胍 疗效 

分 类 号：R4[医药卫生—临床医学]